programme

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote

Sustainability Strategies in the Life Sciences Industry

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

SPEAKERS

DISCUSSION POINTS

Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet

TALK SPONSOR

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote

Sourcing Responsibly – Putting ESG Principles Into Practice

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote

Why the Pharma Industry Must Address their Carbon Footprint

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

Set a calendar reminder

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote

iGAL 2.0: an Accurate Metric for a Greener Future in Drug Manufacturing – a Supply Chain Perspective

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote

Sustainability – What Does it Mean for Excipient Makers and Users?

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote

Sustainable Production of complex API

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.